Status and phase
Conditions
Treatments
About
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to understand what type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and assess its anti-cancer activity as monotherapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
230 participants in 1 patient group
Loading...
Central trial contact
Ziyi Liu
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal